


Peptide5 TFA

Cat. No.:	HY-P2275B
Molecular Formula:	C ₆₂ H ₉₉ F ₃ N ₁₆ O ₂₂ S
Molecular Weight:	1509.6
Sequence:	Val-Asp-Cys-Phe-Leu-Ser-Arg-Pro-Thr-Glu-Lys-Thr
Sequence Shortening:	VDCFLSRPTEKT
Target:	Gap Junction Protein; NOD-like Receptor (NLR)
Pathway:	Cytoskeleton; Immunology/Inflammation
Storage:	Sealed storage, away from moisture and light, under nitrogen
	Powder -80°C 2 years
	-20°C 1 year



* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

SOLVENT & SOLUBILITY

In Vitro

H₂O : 50 mg/mL (33.12 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
	1 mM		0.6624 mL	3.3121 mL	6.6243 mL
	5 mM		0.1325 mL	0.6624 mL	1.3249 mL
	10 mM		0.0662 mL	0.3312 mL	0.6624 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Peptide5 TFA, a connexin 43 mimetic peptide, reduces animals swelling, astrogliosis, and neuronal cell death after spinal cord injury. Peptide5 TFA also inhibits NLRP3 inflammasome, and is an anti-inflammatory agent^{[1][2][3]}.

REFERENCES

- [1]. Simon J O'Carroll, et al. Connexin 43 mimetic peptides reduce swelling, astrogliosis, and neuronal cell death after spinal cord injury. *Cell Commun Adhes.* 2008 May;15(1):27-42.
- [2]. Yilin Mao, et al. Characterisation of Peptide5 systemic administration for treating traumatic spinal cord injured rats. *Exp Brain Res.* 2017 Oct;235(10):3033-3048.
- [3]. Tonkin RS, et al. Attenuation of mechanical pain hypersensitivity by treatment with Peptide5, a connexin-43 mimetic peptide, involves inhibition of NLRP3 inflammasome in nerve-injured mice. *Exp Neurol.* 2018 Feb;300:1-12.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA